Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436742 | 1.00 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL28334298 | 0.92 | GPR119 (0.50) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL3436365 | 0.86 | GPR119 (0.58) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL21953943 | 0.85 | GPR119 (0.56) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL1613087 | 0.85 | GPR119 (0.56) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL21352374 | 0.84 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL21885666 | 0.84 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL30534946 | 0.84 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL73493 | 0.84 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL2160640 | 0.84 | MEN1 (0.57) | GPR119NAMPTKDM4ETHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-112204007-B | Process for preparing 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023078127-A1 | MACROCYCLIC SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | disclosed |
| CN-112204007-A | Process for the preparation of 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| CN-100389113-C | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2008-05-21 | — | — | CN | disclosed |
| CN-1630650-A | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | BDNF, GABRE, NPY5R | GPR119 499/4885NAMPT 868/4885KDM4E 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.